Protocol Establishment for the Prevention of Lamotrigine-induced Skin Rash in Epilepsy Patients

Last updated: July 14, 2017
Sponsor: Seoul National University Hospital
Overall Status: Trial Status Unknown

Phase

2

Condition

Epilepsy

Smallpox

Treatment

N/A

Clinical Study ID

NCT03220256
1605-121-764
  • Ages 18-85
  • All Genders

Study Summary

The investigators intend to find a way to lower drug rash occurrence by applying drug tolerance induction protocol at the beginning of lamotrigine administration.

Genotyping of participants with rash and those without rash after taking lamotrigine and genetic testing to find common gene mutations in these participants.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Adults aged 18-85 years old

  • Epilepsy patients

  • Patients who started Lamotrigine first time

Exclusion

Exclusion Criteria:

  • Those who do not agree with prior consent

  • Women taking oral contraceptives.

  • history of drug rash

  • Taking enzyme-inducing antiepileptic drugs (EIAED) or valproate (VPA)

Study Design

Total Participants: 30
Study Start date:
August 02, 2016
Estimated Completion Date:
August 01, 2018

Connect with a study center

  • Seoul National University Hospital

    Seoul,
    Korea, Republic of

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.